You are here:

salbutamol sulphate (Salbulin MDPI Novoliser)


Following an abbreviated submission

salbutamol (as sulphate) 100 micrograms per dose as powder for inhalation (Salbulin MDPI Novolizer) is accepted for use within NHS Scotland in patients with reversible airways obstruction such as asthma for relief and prevention of asthma symptoms. It may be used in patients in whom treatment with this short-acting beta agonist is appropriate and for whom delivery by a breath-activated dry powder inhaler device offers advantages over other delivery systems. It should be used to relieve asthma symptoms when they occur and to prevent symptoms in circumstances known by the patient to precipitate symptoms, for example prior to exercise or allergen exposure.

It should be used for patients in whom a short-acting beta-agonist is appropriate and for whom a dry powder inhaler is an appropriate delivery device. It has a similar cost to other dry powder inhaled formulations of salbutamol.

Drug Details

Drug Name: salbutamol sulphate (Salbulin MDPI Novoliser)
SMC Drug ID: 504/08
Manufacturer: Meda Pharmaceuticals Ltd
Indication: For patients aged six years and over with reversible airways obstruction, such as asthma, for the relief and prevention of asthma symptoms
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 October 2008